title: FcγRIIb expression in early stage chronic lymphocytic leukemia.
abstract: In normal B-cells, B-cell antigen receptor (BCR) signaling can be negatively regulated by the low-affinity receptor FcγRIIb (CD32b). To better understand the role of FcγRIIb in chronic lymphocytic leukemia (CLL), we correlated its expression on 155 samples from newly-diagnosed Binet A patients with clinical characteristics and outcome. FcγRIIb expression was similar in normal B-cells and leukemic cells, this being heterogenous among patients and within CLL clones. FcγRIIb expression did not correlate with well known prognostic markers [disease stage, serum beta-2 microglobulin (B2M), IGHV mutational status, expression of ZAP-70 and CD38, and cytogenetics] except for a weak concordance with CD49d. Moreover, patients with low FcγRIIb expression (69/155, 44.5%) required therapy earlier than those with high FcγRIIb expression (86/155, 55.5%) (median 151.4 months vs. not reached; p=.071). These results encourage further investigation on the role of FcγRIIb in CLL biology and prognostic significance in larger series of patients.
authors.affiliation: a Laboratory of Oncology/Hematology and Transplantation , Institute of Biomedical Research, IIB Sant Pau , Barcelona , Spain.|b Department of Hematology , Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona , Barcelona , Spain.
authors.forename: Rosa
authors.initials: R
authors.lastname: Bosch
authors.affiliation: a Laboratory of Oncology/Hematology and Transplantation , Institute of Biomedical Research, IIB Sant Pau , Barcelona , Spain.|b Department of Hematology , Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona , Barcelona , Spain.
authors.forename: Alba
authors.initials: A
authors.lastname: Mora
authors.affiliation: a Laboratory of Oncology/Hematology and Transplantation , Institute of Biomedical Research, IIB Sant Pau , Barcelona , Spain.|b Department of Hematology , Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona , Barcelona , Spain.
authors.forename: Eva Puy
authors.initials: EP
authors.lastname: Vicente
authors.affiliation: c Karches Centre for Chronic Lymphocytic Leukemia Research, The Feinstein Institute for Medical Research , Manhasset , NY , USA.
authors.forename: Gerardo
authors.initials: G
authors.lastname: Ferrer
authors.affiliation: d Department of Human Anatomy and Embryology , University of Barcelona , Barcelona , Spain.
authors.forename: Sonia
authors.initials: S
authors.lastname: Jansà
authors.affiliation: c Karches Centre for Chronic Lymphocytic Leukemia Research, The Feinstein Institute for Medical Research , Manhasset , NY , USA.
authors.forename: Rajendra
authors.initials: R
authors.lastname: Damle
authors.affiliation: e MacroGenics, Inc , Rockville , MD , USA.
authors.forename: Sergey
authors.initials: S
authors.lastname: Gorlatov
authors.affiliation: f Haematology/Oncology, Oncology LIJ Medical Centre , Lake Success , NY , USA.
authors.forename: Kanti
authors.initials: K
authors.lastname: Rai
authors.affiliation: g Department of Hematology , Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS , Barcelona , Spain.
authors.forename: Emili
authors.initials: E
authors.lastname: Montserrat
authors.affiliation: h Laboratory of Hematology , Hospital de la Santa Creu i Sant Pau , Barcelona , Spain.
authors.forename: Josep
authors.initials: J
authors.lastname: Nomdedeu
authors.affiliation: h Laboratory of Hematology , Hospital de la Santa Creu i Sant Pau , Barcelona , Spain.
authors.forename: Marta
authors.initials: M
authors.lastname: Pratcorona
authors.affiliation: h Laboratory of Hematology , Hospital de la Santa Creu i Sant Pau , Barcelona , Spain.
authors.forename: Laura
authors.initials: L
authors.lastname: Blanco
authors.affiliation: b Department of Hematology , Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona , Barcelona , Spain.
authors.forename: Silvana
authors.initials: S
authors.lastname: Saavedra
authors.affiliation: b Department of Hematology , Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona , Barcelona , Spain.
authors.forename: Ana
authors.initials: A
authors.lastname: Garrido
authors.affiliation: b Department of Hematology , Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona , Barcelona , Spain.
authors.forename: Albert
authors.initials: A
authors.lastname: Esquirol
authors.affiliation: b Department of Hematology , Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona , Barcelona , Spain.
authors.forename: Irene
authors.initials: I
authors.lastname: Garcia
authors.affiliation: b Department of Hematology , Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona , Barcelona , Spain.
authors.forename: Miquel
authors.initials: M
authors.lastname: Granell
authors.affiliation: b Department of Hematology , Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona , Barcelona , Spain.
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Martino
authors.affiliation: g Department of Hematology , Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS , Barcelona , Spain.
authors.forename: Julio
authors.initials: J
authors.lastname: Delgado
authors.affiliation: a Laboratory of Oncology/Hematology and Transplantation , Institute of Biomedical Research, IIB Sant Pau , Barcelona , Spain.|b Department of Hematology , Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona , Barcelona , Spain.
authors.forename: Jorge
authors.initials: J
authors.lastname: Sierra
authors.affiliation: c Karches Centre for Chronic Lymphocytic Leukemia Research, The Feinstein Institute for Medical Research , Manhasset , NY , USA.
authors.forename: Nicholas
authors.initials: N
authors.lastname: Chiorazzi
authors.affiliation: a Laboratory of Oncology/Hematology and Transplantation , Institute of Biomedical Research, IIB Sant Pau , Barcelona , Spain.|b Department of Hematology , Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona , Barcelona , Spain.
authors.forename: Carol
authors.initials: C
authors.lastname: Moreno
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D017452:Receptors, IgG / Q000378:metabolism*; D051746:ZAP-70 Protein-Tyrosine Kinase / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; C080571:Fc gamma receptor IIB; D017452:Receptors, IgG; D051746:ZAP-70 Protein-Tyrosine Kinase; C497261:ZAP70 protein, human
keywords: B-cell activation; B-cell receptor; Chronic lymphocytic leukemia; FcγRIIb; treatment-free survival